The polycomb group protein EZH2 inhibits lung cancer cell growth by repressing the transcription factor Nrf2

FEBS Letters

Volumn 588, Issue 17, 2014, Pages 3000-3007

  Li, Ziming ^a   Xu, Ling ^b   Tang, Naiwang ^a   Xu, Yunhua ^a   Ye, Xiangyun ^a   Shen, Shengping ^a   Niu, Xiaomin ^a   Lu, Shun ^a   Chen, Zhiwei ^a  

^a SHANGHAI JIAO TONG UNIVERSITY   (China)

^b LONGHUA HOSPITAL AFFILIATED TO SHANGHAI UNIVERSITY OF TRADITIONAL CHINESE MEDICINE   (China)

Author keywords

Enhancer of zester homolog 2; Histone H3 lysine 27; NF E2 related factor 2; Non small cell lung cancer

Indexed keywords

HISTONE H3; MESSENGER RNA; TRANSCRIPTION FACTOR EZH2; TRANSCRIPTION FACTOR NRF2;

ADULT; ANIMAL EXPERIMENT; ANIMAL MODEL; ARTICLE; CANCER GROWTH; CANCER INHIBITION; CANCER SURVIVAL; CELL PROLIFERATION; COLONY FORMATION; CONTROLLED STUDY; DOWN REGULATION; FEMALE; GENE EXPRESSION; HUMAN; HUMAN CELL; HUMAN TISSUE; IN VITRO STUDY; IN VIVO STUDY; LUNG CANCER CELL LINE; LUNG NON SMALL CELL CANCER; MAJOR CLINICAL STUDY; MALE; MOUSE; NONHUMAN; NUCLEOTIDE SEQUENCE; PREDICTION; PRIORITY JOURNAL; PROMOTER REGION; PROTEIN EXPRESSION; PROTEIN PROTEIN INTERACTION; TUMOR XENOGRAFT;

ENHANCER OF ZESTER HOMOLOG 2; HISTONE H3 LYSINE 27; NF-E2-RELATED FACTOR 2; NON-SMALL CELL LUNG CANCER;

CARCINOMA, NON-SMALL-CELL LUNG; CELL LINE, TUMOR; CELL PROLIFERATION; DISEASE PROGRESSION; EPIGENESIS, GENETIC; FEMALE; HISTONES; HUMANS; LUNG NEOPLASMS; LYSINE; MALE; METHYLATION; MIDDLE AGED; NF-E2-RELATED FACTOR 2; POLYCOMB REPRESSIVE COMPLEX 2; SURVIVAL ANALYSIS;

EID: 84906257946     PISSN: 00145793     EISSN: 18733468     Source Type: Journal    
DOI: 10.1016/j.febslet.2014.05.057     Document Type: Article

References (28)

1. E.L. Greer, and Y. Shi Histone methylation: a dynamic mark in health, disease and inheritance Nat. Rev. Genet. 13 2012 343 357
2. Joshua C. Black, C. Van Rechem, and Johnathan R. Whetstine Histone lysine methylation dynamics: establishment, regulation, and biological impact Mol. Cell 48 2012 491 507
3. A. Chase, and N.C.P. Cross Aberrations of EZH2 in Cancer Clin. Cancer Res. 17 2011 2613 2618
4. P. Chi, C.D. Allis, and G.G. Wang Covalent histone modifications - miswritten, misinterpreted and mis-erased in human cancers Nat. Rev. Cancer 10 2010 457 469
5. M. Albert, and K. Helin Histone methyltransferases in cancer Semin. Cell Dev. Biol. 21 2010 209 220
6. S. Varambally, S.M. Dhanasekaran, M. Zhou, T.R. Barrette, C. Kumar-Sinha, M.G. Sanda, D. Ghosh, K.J. Pienta, R.G. Sewalt, A.P. Otte, M.A. Rubin, and A.M. Chinnaiyan The polycomb group protein EZH2 is involved in progression of prostate cancer Nature 419 2002 624 629
7. C.G. Kleer, Q. Cao, S. Varambally, R. Shen, I. Ota, S.A. Tomlins, D. Ghosh, R.G. Sewalt, A.P. Otte, D.F. Hayes, M.S. Sabel, D. Livant, S.J. Weiss, M.A. Rubin, and A.M. Chinnaiyan EZH2 is a marker of aggressive breast cancer and promotes neoplastic transformation of breast epithelial cells Proc. Natl. Acad. Sci. U.S.A. 100 2003 11606 11611
8. H.P. Visser, M.J. Gunster, H.C. Kluin-Nelemans, E.M. Manders, F.M. Raaphorst, C.J. Meijer, R. Willemze, and A.P. Otte The polycomb group protein EZH2 is upregulated in proliferating, cultured human mantle cell lymphoma Br. J. Haematol. 112 2001 950 958
9. J.W. Kaspar, S.K. Niture, and A.K. Jaiswal Nrf 2:INrf2 (Keap1) signaling in oxidative stress Free Radic. Biol. Med. 47 2009 1304 1309
10. A.K. Jaiswal Nrf2 signaling in coordinated activation of antioxidant gene expression Free Radic. Biol. Med. 36 2004 1199 1207
11. S. Homma, Y. Ishii, Y. Morishima, T. Yamadori, Y. Matsuno, N. Haraguchi, N. Kikuchi, H. Satoh, T. Sakamoto, N. Hizawa, K. Itoh, and M. Yamamoto Nrf2 enhances cell proliferation and resistance to anticancer drugs in human lung cancer Clin. Cancer Res. 15 2009 3423 3432
12. T.M. Stȩpkowski, and M.K. Kruszewski Molecular cross-talk between the NRF2/KEAP1 signaling pathway, autophagy, and apoptosis Free Radic. Biol. Med. 50 2011 1186 1195
13. D.D. Zhang The Nrf2-Keap1-ARE signaling pathway: the regulation and dual function of Nrf2 in cancer Antioxid. Redox Signal. 13 2010 1623 1626
14. A. Singh, V. Misra, R.K. Thimmulappa, H. Lee, S. Ames, M.O. Hoque, J.G. Herman, S.B. Baylin, D. Sidransky, E. Gabrielson, M.V. Brock, and S. Biswal Dysfunctional KEAP1-NRF2 interaction in non-small-cell lung cancer PLoS Med. 3 2006 e420
15. T. Ohta, K. Iijima, M. Miyamoto, I. Nakahara, H. Tanaka, M. Ohtsuji, T. Suzuki, A. Kobayashi, J. Yokota, T. Sakiyama, T. Shibata, M. Yamamoto, and S. Hirohashi Loss of Keap1 function activates nrf2 and provides advantages for lung cancer cell growth Cancer Res. 68 2008 1303 1309
16. B. Padmanabhan, K.I. Tong, T. Ohta, Y. Nakamura, M. Scharlock, M. Ohtsuji, M.-I. Kang, A. Kobayashi, S. Yokoyama, and M. Yamamoto Structural basis for defects of Keap1 activity provoked by its point mutations in lung cancer Mol. Cell 21 2006 689 700
17. A. Singh, M. Bodas, N. Wakabayashi, F. Bunz, and S. Biswal Gain of Nrf2 function in non-small-cell lung cancer cells confers radioresistance Antioxid. Redox Signal. 13 2010 1627 1637
18. Z. Chen, X. Ye, N. Tang, S. Shen, Z. Li, X. Niu, S. Lu, and L. Xu HMOF acetylates Nrf2 and regulates anti-drug responses in human non-small cell lung cancer Br. J. Pharmacol. 171 2014 3196 3211
19. Y.n. Li, D. Dai, Q. Lu, M. Fei, M. Li, and X. Wu Sirt2 suppresses glioma cell growth through targeting NF-κB-miR-21 axis Biochem. Biophys. Res. Commun. 441 2013 661 667
20. W. Han, Z. Xin, Z. Zhao, W. Bao, X. Lin, B. Yin, J. Zhao, J. Yuan, B. Qiang, and X. Peng RNA-binding protein PCBP2 modulates glioma growth by regulating FHL3 J. Clin. Invest. 123 2013 2103 2118
21. T. Yamadori, Y. Ishii, S. Homma, Y. Morishima, K. Kurishima, K. Itoh, M. Yamamoto, Y. Minami, M. Noguchi, and N. Hizawa Molecular mechanisms for the regulation of Nrf2-mediated cell proliferation in non-small-cell lung cancers Oncogene 31 2012 4768 4777
22. G. Rachakonda, K.R. Sekhar, D. Jowhar, P.C. Samson, J.P. Wikswo, R.D. Beauchamp, P.K. Datta, and M.L. Freeman Increased cell migration and plasticity in Nrf2-deficient cancer cell lines Oncogene 29 2010 3703 3714
23. S. Balasubramanian, S. Kanade, B. Han, and R.L. Eckert A proteasome inhibitor-stimulated Nrf1 protein-dependent compensatory increase in proteasome subunit gene expression reduces polycomb group protein level J. Biol. Chem. 287 2012 36179 36189
24. Q. Cao, J. Yu, S.M. Dhanasekaran, J.H. Kim, R.S. Mani, S.A. Tomlins, R. Mehra, B. Laxman, X. Cao, J. Yu, C.G. Kleer, S. Varambally, and A.M. Chinnaiyan Repression of E-cadherin by the polycomb group protein EZH2 in cancer Oncogene 27 2008 7274 7284
25. A.P. Bracken, D. Pasini, M. Capra, E. Prosperini, E. Colli, and K. Helin EZH2 is downstream of the pRB-E2F pathway, essential for proliferation and amplified in cancer EMBO J. 22 2003 5323 5335
26. I.M. Bachmann, O.J. Halvorsen, K. Collett, I.M. Stefansson, O. Straume, S.A. Haukaas, H.B. Salvesen, A.P. Otte, and L.A. Akslen EZH2 expression is associated with high proliferation rate and aggressive tumor subgroups in cutaneous melanoma and cancers of the endometrium, and breast J. Clin. Oncol. 24 2006 268 273
27. G. Nikoloski, S.M. Langemeijer, R.P. Kuiper, R. Knops, M. Massop, E.R. Tonnissen, A. van der Heijden, T.N. Scheele, P. Vandenberghe, T. de Witte, B.A. van der Reijden, and J.H. Jansen Somatic mutations of the histone methyltransferase gene EZH2 in myelodysplastic syndromes Nat. Genet. 42 2010 665 667
28. T. Shibata, T. Ohta, K.I. Tong, A. Kokubu, R. Odogawa, K. Tsuta, H. Asamura, M. Yamamoto, and S. Hirohashi Cancer related mutations in NRF2 impair its recognition by Keap1-Cul3 E3 ligase and promote malignancy Proc. Natl. Acad. Sci. 105 2008 13568 13573